How Much Revenue Is at Risk Under the 2027 CLFS Changes?

Prepare for the return of PAMA-driven payment reductions in 2027 and explore the potential financial impact on laboratory revenue.

With PAMA payment reductions expected to resume in 2027 and hundreds of laboratory CPT codes potentially facing reimbursement pressure, lab leaders are closely evaluating one critical question: How will Medicare reimbursement change?

While the CY 2027 Medicare Physician Fee Schedule (MPFS) Proposed Rule remains subject to public comment and finalization, it provides important insight into the reimbursement environment clinical laboratories and pathology groups should prepare for in 2027. Comments on the proposed rule are due September 14, 2026, with the final rule expected later this fall.

PAMA Payment Reductions Expected to Resume

One of the most significant developments for laboratories is the expected resumption of payment reductions under the Protecting Access to Medicare Act (PAMA). Beginning in 2027, Medicare payment reductions for applicable clinical diagnostic laboratory tests are anticipated to resume, with annual decreases capped at 15% through 2029.

While the cap limits the severity of year-over-year reductions, laboratories that perform high volumes of routine testing could still experience meaningful revenue impacts over time.

What History Tells Us About Potential 2027 CLFS Cuts

Laboratories do not have to speculate about the potential impact of renewed Clinical Laboratory Fee Schedule (CLFS) repricing. The first PAMA implementation cycle provides a useful benchmark.

When CMS recalculated CLFS rates using private payer data:

• Industry groups estimate the initial PAMA implementation resulted in approximately $3.8 billion in Medicare laboratory payment reductions over three years.

• Approximately 75% of laboratory test codes experienced payment reductions.

The commercial payer data reported during the 2026 reporting period will be used to establish CLFS rates for 2027 through 2029. Prior to Congressional intervention, laboratory organizations estimated that nearly 800 CPT codes could face reductions of up to 15% under the next cycle.

Common Tests Historically Impacted by PAMA

These tests are particularly sensitive because they combine high utilization with relatively modest reimbursement rates, meaning even small percentage reductions can create significant aggregate revenue losses.

For laboratories performing hundreds of thousands of chemistry, hematology, diabetes, and coagulation tests annually, even a single-digit reimbursement decrease can have a substantial cumulative financial impact.

Medicare's Influence Extends Beyond Medicare

Although routine laboratory testing is reimbursed through the CLFS, Medicare is often only the starting point. Many commercial payer agreements are directly or indirectly influenced by Medicare benchmarks. As Medicare rates change, laboratories frequently see impacts on:

• Commercial payer reimbursement trends

• Contract negotiations

• Revenue forecasting

• Long-term profitability

Why Laboratories Should Pay Attention Now

As reimbursement reductions resume, organizations may encounter:

• Increased pressure on operating margins

• Greater scrutiny of service-line profitability

• More challenging payer negotiations

• Increased focus on reimbursement optimization

• Greater need for accurate reimbursement forecasting

An Important Opportunity to Comment

The CY 2027 MPFS Proposed Rule gives laboratories a valuable opportunity to provide CMS with real-world data on the consequences of reimbursement reductions. Consider including:

• Historical impacts of prior PAMA reductions

• Revenue-at-risk analyses for high-volume CPT codes

• Cost inflation related to labor, reagents, and technology

• Access concerns for rural, community, and hospital-based laboratories

• Recommendations for more representative market-rate data collection

Many industry stakeholders have argued that previous PAMA data collection disproportionately reflected rates from large national laboratories and underrepresented hospital and community-based laboratories. The current comment period gives laboratories an opportunity to ensure CMS understands the real-world impact of proposed reimbursement changes.

Looking Ahead

The expected return of PAMA-driven reimbursement reductions marks a pivotal moment for the laboratory industry. Historical experience demonstrates that even modest reductions to high-volume tests can compound into significant financial pressure, affecting margins, staffing, technology investments, and patient access to care. As laboratories prepare for the possibility of reimbursement changes beginning in 2027, understanding their exposure is only the first step.

With comments due by September 14, 2026, laboratory leaders have a critical opportunity to ensure CMS hears directly from the organizations that will be most affected. By sharing data, operational insights, and patient access considerations, laboratories can help inform the final rule and contribute to a reimbursement framework that more accurately reflects the realities of today's laboratory environment.